No Data
Is NanJing Pharmaceutical (SHSE:600713) Using Too Much Debt?
nanjing pharmaceutical (600713.SH) has been approved to register 6 billion yuan of ultra-short-term financing bonds.
Nanjing Pharmaceutical(600713.SH) announced that the company received a notice from Bank of China on October 30, 2024...
Nanjing Pharmaceutical: Full text of Nanjing Pharmaceutical\'s 2024 third quarter report
Full text of Nanjing Pharmaceutical\'s 2024 third quarter report
Nanjing Pharmaceutical (600713.SH) released its performance for the first three quarters, with net income of 0.442 billion yuan, a 0.36% year-on-year increase.
nanjing pharmaceutical (600713.SH) released the third quarter report for 2024, with revenue for the first three quarters reaching 40...
Nanjing Pharmaceutical (600713.SH): The net income for the first three quarters was 0.442 billion yuan, a year-on-year increase of 0.36%.
Gelonghui October 30th | Nanjing Pharmaceutical (600713.SH) announced the third quarter report of 2024, with the company's revenue in the first three quarters of 40.938 billion yuan, a year-on-year increase of 0.97%; net income attributable to shareholders of the listed company was 0.442 billion yuan, a year-on-year increase of 0.36%; basic earnings per share was 0.34 yuan.
What NanJing Pharmaceutical Company Limited's (SHSE:600713) ROE Can Tell Us
